Text Size: a  |   a 

Study Says Older Immunosuppressants May Increase MS Patients' Cancer Risk

August 17, 2017

The risk of people with multiple sclerosis developing cancer is higher if they have used immunosuppressants than if they haven’t, according to a study that followed more than 1,000 patients for a decade.

The findings indicate that the often discussed association between MS and cancer may stem from older types of MS treatments rather than from the disease itself.
MS patients not treated with immunosuppressants had similar cancer risks as people in the general population, according to the study, “Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study.” It was published in the journal BMC Neurology.
Before the development of newer disease-modifying therapies, patients who failed to respond to interferons or Copaxone (glatiramer acetate) were often offered harsher treatments.

Modern disease-modifying treatments target selected immune system players. In contrast, immunosuppressant drugs — such as azathioprine, mitoxantrone, and cyclophosphamide — eliminate an entire spectrum of immune cells. They also permanently alter the activity of cancer-causing genes, researchers have discovered.

To gain insight into immunosuppressants’ role in MS patients developing cancer, researchers at the University of Palermo in Italy recruited 531 people with MS who had used the therapies. The group was composed of 346 women and 185 men.
As controls, the research team recruited 531 MS patients who had never been treated with immunosuppression. They compared both groups to people of the same age in the general population from the same area.

Researchers followed patients who used immunosuppressants an average of nine years, and untreated patients about 10 years.